期刊文献+

转运蛋白基因多态性对儿童急性淋巴细胞白血病大剂量甲氨蝶呤治疗的影响 被引量:15

Influence of transport protein gene polymorphisms on the effects and toxicity of high-dose methotrexate in childhood acute lymphoblastic leukemia
下载PDF
导出
摘要 目的研究多药耐药基因1(MDR1)和还原型叶酸载体基因(SLC19A1)多态性对儿童急性淋巴细胞白血病(ALL)大剂量甲氨喋呤(MTX)治疗疗效及不良反应的影响。方法应用基质辅助激光解吸电离飞行时间质谱(MALDI-TOFMS)技术,对108例ALL患者MDR1 exon26C>T、MDR1 exon21G>T/A和SLC19A1 80G>A基因多态性进行分析;并分析基因型和生存率、不良反应等的关系。结果 MDR1 exon26C>T、MDR1 exon21G>T/A和SLC19A180G>A各基因型的36个月生存率差异无统计学意义;MDR1 exon26C>T和MDR1 exon21G>T/A突变型的24 h MTX血浆浓度高于野生型,且突变型具有更高的肝功能损伤发生率,差异均有统计学意义(P<0.05)。结论 MDR1 exon26C>T和MDR1 exon21G>T/A基因突变对大剂量MTX治疗血浆浓度及肝功能损伤有明显影响。 Objectives To investigate the influence of polymorphisms of SLC19A1 80G&gt;A,MDR1 exon26C&gt;T and MDR1 exon21G&gt;T/A on curative effect and adverse reaction of high-dose methotrexate in patients with acute lymphoblastic leukemia.Methods MALDI-TOF-MS technique was used to detect the polymorphisms of SLC19A1 80G&gt;A,MDR1 exon 26C&gt;T and MDR1 exon21G&gt;T/A in 108 patients with acute lymphoblastic leukemia(ALL).The relationship of genetic polymorphism,survival rate and toxicity was analyzed.Results The 36-month event-free survival was not related to any polymorphisms of MDR1 and SLC19A1.Patients with mutant types of MDR1 exon26C&gt;T and MDR1 exon21G&gt;T/A showed a much higher MTX plasma levels at 24 hours and higher incidence of hepatic injury(P&lt;0.05).Conclusions The genetic polymorphism of MDR1 exon26&gt;T,MDR1 exon21G&gt;T/A has a large influence on hepatic toxicity and plasma concentrations of MTX.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2013年第8期733-736,共4页 Journal of Clinical Pediatrics
关键词 多药耐药基因1 还原性叶酸载体 基因多态性 急性淋巴细胞白血病 甲氨蝶呤 multidrug resistance gene 1 reduced folate carrier genetic polymorphism acute lymphoblastic leukemia methotrexate
  • 相关文献

参考文献9

  • 1Gervasini G, Vagace JM. Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leuke- mia [J]. Front Genet, 2012, 3: 249.
  • 2顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 3Kishi S, Cheng C, Frech D, et al. Ancestry and pharmacoge- netics of antileukemic drug toxicity [J]. Blood, 2007, 109(10): 4151-4157.
  • 4Kim H, Kang H J, Kim H J, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possi- ble association between survival rate and ITPA polymorphism [J]. PLoS One, 2012, 7(9): e45558.
  • 5Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia [J]. Blood, 2005, 105(12): 4752-4758.
  • 6徐康康,廖清船,张永,许静,罗琳,王春旭,彭宵霞.MTHFR C677T和RFC1 G80A基因多态性对急性淋巴细胞白血病患儿大剂量甲氨蝶呤化疗不良反应的影响[J].实用儿科临床杂志,2009,24(21):1674-1676. 被引量:18
  • 7Hamidovic A, Hahn K, Kolesar J. Clinical significance of ABCB1 genotyping in oncology [J]. J Oncol Pharma Pract, 2010, 16(1): 39-44.
  • 8Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silem" poly- morphism in the MDR1 gene changes substrate specificity [J]. Science, 2007, 315(5811): 525-528.
  • 9Azarpira N, Aghdaie MH, Behzad-Behbahanie A, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation [J]. Exp Clin Transplant, 2006, 4(1): 416-419.

二级参考文献12

  • 1徐卫群,汤永民,方澄清,宋华,石淑文,扬世隆,任鼎泰,沈红强,钱伯芹.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病排泄延迟分析[J].中华血液学杂志,2005,26(1):15-18. 被引量:66
  • 2顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 3Ongaro A,de Mattei M, Della Porta MG,et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: Effects on methotrexaterelated toxicity and survival [ J]. Haematologica,2009,94 ( 10 ) : 1391 - 1398.
  • 4Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis [ J ]. J Rheumatol,2008,35 (4) :572 - 579.
  • 5Bohanec Grabar P, Logar D, Lestan B, et al. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients : A study of polymorphisms affecting methotrexate transport and folate metabolism[ J]. Eur J Clin Pharmacol,2008,64( 11 ) : 1057 - 1068.
  • 6Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and gamma - glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis[ J]. Pharntaeogenetics ,2004,14 ( 11 ) : 733 - 739.
  • 7Laverdiere C, Chiasson S, Costea I, et al. Polymorphism GSOA in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia [ J ]. Blood ,2002,100 ( 10 ) :3832 - 3834.
  • 8lmanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma [ J ]. J Hum Genet, 2007,52 ( 2 ) : 166 - 171.
  • 9Galivan J, Pupons A, Rhee MS. Hepatic parenchymal cell glutamylation of methotrexate studied in monolayer culture [ J ]. Cancer Res, 1986,46 (2) :670-675.
  • 10Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity [ J ]. J Rheumatol,2009,36 ( 3 ) :539 - 545.

共引文献488

同被引文献93

引证文献15

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部